Efficacy and Safety of Shenzhu Jianyun Tiaoqi Decoction(参术健运调气汤)Combined with Chemotherapy for Advanced Esophageal Carcinoma with Spleen Deficiency and Qi Stagnation
Objective To explore the efficacy and safety of Shenzhu Jianyun Tiaoqi Decoction(参术健运调气汤)combined with chemotherapy in the treatment of advanced esophageal cancer with spleen deficiency and Qi stagnation.Method A total of 88 patients with advanced esophageal cancer with spleen deficiency and Qi stagnation were selected from February 2020 to February 2022.According to the random number table method,they were divided into control group[44 cases,capecitabine+oxaliplatin(XELOX)chemotherapy]and observation group(44 cases,XELOX chemotherapy+Shenzhu Jianyun Tiaoqi Decoction).Tradi-tional Chinese medicine symptom scores were compared between the two groups before and after treatment,the clinical efficacy 6 weeks after chemotherapy,bone marrow suppression,the levels of serum vascular endothelial growth factor(VEGF)and cytokera-tin 19 fragment antigen(CYFRA21-1)before and 1 week after treatment,and adverse reactions during chemotherapy were ana-lyzed.Results There was no significant difference between the two groups before treatment(P＞0.05)in the scores of primary disease,secondary disease or total score,and after treatment they were all lower than those before treatment(P＜0.05),and the scores of the observation group were lower than those of the observation group(P＜0.05).The curative effect of the two groups was statistically significant by rank sum test(P＜0.05),and the curative effect of the observation group was better than that of the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Before treatment,there were no significant differences in the levels of CYFRA21-1 or VEGF between two groups(P＞0.05).After treatment,the levels of CYFRA21-1 and VEGF in two groups were decreased,and the levels in observation group were lower than those in control group(P＜0.05).There were 3 cases lost to follow-up,including 1 case in the observation group and 2 cases in the control group.The follow-up rate was 96.59％.In the observation group,18 patients died,and the 1-year survival rate was 59.09％.In control group,29 patients died,and the 1-year survival rate was 34.09％.The 1-year sur-vival rate of the observation group was higher than that of the control group,and the difference in survival curve between the two groups was statistically significant(Log-rank=2.898,P＜0.05).Conclusion Shenshu Jianyun Tiaoqi Decoction combined with chemotherapy can relieve the symptoms of advanced esophageal cancer with spleen deficiency and Qi stagnation,has superior clin-ical efficacy,and can effectively regulate the levels of tumor-related factors with good safety.
万方数据
维普
